Valuation: ARS Pharmaceuticals, Inc.

Market Cap 427M 379M 355M 322M 607M 41.17B 612M 4.26B 1.66B 21B 1.6B 1.57B 67.53B P/E 2026 *
-2.32x
P/E 2027 * -5.08x
Enterprise Value 427M 379M 355M 322M 607M 41.17B 612M 4.26B 1.66B 21B 1.6B 1.57B 67.53B EV / Sales 2026 *
3.29x
EV / Sales 2027 * 2.24x
Free-Float
83.82%
Yield 2026 *
-
Yield 2027 * -
1 day+0.12%
1 week-2.39%
Current month-0.35%
1 month-23.58%
3 months-48.44%
6 months-48.81%
Current year-63.13%
1 week 3.98
Extreme 3.985
4.4
1 month 3.98
Extreme 3.985
5.54
Current year 3.98
Extreme 3.985
13.15
1 year 3.98
Extreme 3.985
13.15
3 years 3.35
Extreme 3.35
18.9
5 years 2.55
Extreme 2.55
18.9
10 years 2.55
Extreme 2.55
18.9
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 05/08/2015
Chief Executive Officer 53 07/07/2026
Director of Finance/CFO 57 01/02/2022
Director TitleAgeSince
Chairman 56 08/11/2022
Director/Board Member 55 01/08/2021
Director/Board Member 56 01/07/2017
Date Insider Type Main position Quantity % Market Cap. Importance
01/10/26 Free

Chief Executive Officer

1,036,923 1.0427%
01/09/26 Free

Executive/Senior Manager

1,001,738 1.0073%
01/07/26 Free

Chief Executive Officer

898,456 0.9048%
Change 5-day change 1-year change 3-year change Capi.($)
+0.12%-2.39%-58.18%+0.59% 427M
+4.16%+4.16%+49.37%+94.17% 74.69B
-1.61%-3.00%+20.97%+75.89% 58.81B
-0.10%+0.17%+6.66%+34.31% 48.45B
-3.76%-2.25%+329.09%+698.20% 42.84B
-2.30%-3.35%+26.81%+30.88% 42.79B
+0.31%-0.68%+5.30%+108.64% 41.25B
-0.11%+1.96%+9.19%+52.66% 31.13B
-2.07%+1.16%+35.00%+26.28% 30.28B
-1.96%-2.88%-8.97%-13.92% 24.05B
Average -0.73%-0.47%+41.52%+110.77% 39.47B
Weighted average by Cap. -0.38%-0.54%+55.26%+129.14%

Financials

2026 *2027 *
Net sales 130M 115M 108M 97.82M 185M 12.52B 186M 1.3B 504M 6.39B 488M 477M 20.54B 191M 169M 158M 144M 271M 18.37B 273M 1.9B 740M 9.37B 715M 700M 30.13B
Net income -184M -163M -153M -139M -262M -17.74B -264M -1.84B -714M -9.05B -691M -676M -29.09B -85.02M -75.47M -70.63M -64.02M -121M -8.2B -122M -848M -330M -4.18B -319M -312M -13.44B
Net Debt - -
Projected Income Statement - Annual - ARS Pharmaceuticals, Inc.
Logo ARS Pharmaceuticals, Inc.
ARS Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy, an epinephrine nasal spray indicated in the United States for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. neffy is an FDA and European Commission (EC)-approved needle-free epinephrine product, and also has approvals in the United Kingdom, Japan, Australia, and China. It is advancing its nasal spray development program across multiple Type I hypersensitivity reactions, including acute flares of urticaria.
Employees
198
Date Price Change Volume
06/10/26 $4.295 +0.12% 1,219,176
05/10/26 $4.290 +5.41% 1,621,610
02/10/26 $4.070 -1.21% 1,828,672
01/10/26 $4.120 -4.41% 1,971,566
30/09/26 $4.310 -2.05% 1,298,238
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Ratings Surperformance© - ARS Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.295USD
Average target price
22.50USD
Spread / Average Target
+423.86%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - ARS Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. SPRY Stock